stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Return on invested capital
argenex SE's return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 17.2 percentage points from fiscal 2025 (17.2%). Over the past ten years it has ranged from −65.3% (fiscal 2020) to 17.2% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 17.2% | 17.53 |
| FY2024 | −0.34% | 12.63 |
| FY2023 | −13.0% | 9.40 |
| FY2022 | −22.4% | (4.20) |
| FY2021 | −18.2% | 47.11 |
| FY2020 | −65.3% | (49.77) |
| FY2019 | −15.5% | 4.50 |
| FY2018 | −20.0% | (10.60) |
| FY2017 | −9.41% | (9.41) |
| FY2016 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 85.2% |
| INCY Incyte Corporation compare | 21.6% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 11.6% |
| GMAB Genmab A/S Sponsored ADR compare | 6.99% |
| RPRX Royalty Pharma PLC compare | 5.24% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| ARGX argenex SE | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −34.5% |
| MRNA Moderna, Inc. compare | −93.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement